Actively Recruiting
Venous Ethanol for Ventricular Tachycardia
Led by The Methodist Hospital Research Institute · Updated on 2026-03-30
156
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial
CONDITIONS
Official Title
Venous Ethanol for Ventricular Tachycardia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 85 years with a prior implantable cardioverter defibrillator (ICD)
- Diagnosed with ischemic cardiomyopathy confirmed by prior heart attack or imaging showing regional heart muscle damage
- Experienced one of the following VT events within the last 6 months: three or more VT episodes treated with anti-tachycardia pacing or anti-arrhythmic drugs; one or more appropriate ICD shocks; three or more VT episodes within 24 hours; or sustained VT below ICD detection documented by ECG or monitor
- Deemed suitable candidates for radiofrequency ablation of VT
- Able and willing to comply with all study requirements before, during, and after treatment
- Willing to sign informed consent
You will not qualify if you...
- Serum creatinine above 1.5 mg/dL or creatinine clearance below 30 ml/min
- Left ventricular ejection fraction 10% or less
- Presence of mobile left ventricular thrombus on echocardiography
- No vascular access to the left ventricle
- Disease expected to limit survival to less than 12 months
- New York Heart Association class IV heart failure
- Cardiac surgery within the past 2 months, unless VT was incessant
- Acute coronary syndrome in the past 2 months with thrombus or dynamic ECG changes
- Reversible causes of VT such as electrolyte imbalance or drug-induced arrhythmia
- Severe aortic stenosis or mitral regurgitation with flail leaflet
- Pregnancy
- Unwilling or unable to provide informed consent
- Positive Covid-19 test within 14 days before randomization
- Enrolled or planning enrollment in another research study during this trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Houston Methodist Hospital
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
I
Iris Melissa Alanis
CONTACT
C
Casey Kappenman
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here